Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midolla Osseo (GITMO)

A. Bosi, S. Bacci, R. Miniero, F. Locatelli, D. Laszlo, G. Longo, A. Busca, M. T. Van Lint, P. Di Bartolomeo, A. Amici

Research output: Contribution to journalArticle

Abstract

Thirty-eight second allogeneic bone marrow transplants (BMT) for acute leukemia relapsed after first BMT were performed in 13 Italian centers between 1987 and 1994. Twenty-one patients had acute myelogenous leukemia (AML), 17 acute lymphoblastic leukemia (ALL); at second BMT 24 patients were in complete remission (CR) and 14 in relapse. The median time to relapse after first BMT was 10 months (range 1-70). Grade II or greater acute graft-versus-host disease (GVHD) after second transplant occurred in 34.2% of patients and a chronic GVHD in 31.5% of patients. Twenty-four patients died: seven from early transplant-related mortality (TRM), 13 from relapse and four from late toxicity. As of 31 July 1996, at a median follow-up of 47 months (range 22-85), there are 14 survivors. The three-year probability of TRM, relapse and event-free survival (EFS) is 28%, 40% and 42% respectively. In 20 of 27 evaluable patients, remission duration after second BMT was longer than after the first BMT. A diagnosis of AML was correlated with a better outcome. These data support the usefulness of second allograft in selected patients with AML relapsing after a first BMT.

Original languageEnglish
Pages (from-to)420-424
Number of pages5
JournalLeukemia
Volume11
Issue number3
Publication statusPublished - 1997

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Multicenter Studies
Leukemia
Transplants
Bone Marrow
Acute Myeloid Leukemia
Recurrence
Graft vs Host Disease
Mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
Allografts
Survivors

Keywords

  • Acute leukemia
  • Relapse
  • Second BMT

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Second allogeneic bone marrow transplantation in acute leukemia : A multicenter study from the Gruppo Italiano Trapianto Di Midolla Osseo (GITMO). / Bosi, A.; Bacci, S.; Miniero, R.; Locatelli, F.; Laszlo, D.; Longo, G.; Busca, A.; Van Lint, M. T.; Di Bartolomeo, P.; Amici, A.

In: Leukemia, Vol. 11, No. 3, 1997, p. 420-424.

Research output: Contribution to journalArticle

Bosi, A. ; Bacci, S. ; Miniero, R. ; Locatelli, F. ; Laszlo, D. ; Longo, G. ; Busca, A. ; Van Lint, M. T. ; Di Bartolomeo, P. ; Amici, A. / Second allogeneic bone marrow transplantation in acute leukemia : A multicenter study from the Gruppo Italiano Trapianto Di Midolla Osseo (GITMO). In: Leukemia. 1997 ; Vol. 11, No. 3. pp. 420-424.
@article{329b1e61ac7c423a85abc000d1778adb,
title = "Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midolla Osseo (GITMO)",
abstract = "Thirty-eight second allogeneic bone marrow transplants (BMT) for acute leukemia relapsed after first BMT were performed in 13 Italian centers between 1987 and 1994. Twenty-one patients had acute myelogenous leukemia (AML), 17 acute lymphoblastic leukemia (ALL); at second BMT 24 patients were in complete remission (CR) and 14 in relapse. The median time to relapse after first BMT was 10 months (range 1-70). Grade II or greater acute graft-versus-host disease (GVHD) after second transplant occurred in 34.2{\%} of patients and a chronic GVHD in 31.5{\%} of patients. Twenty-four patients died: seven from early transplant-related mortality (TRM), 13 from relapse and four from late toxicity. As of 31 July 1996, at a median follow-up of 47 months (range 22-85), there are 14 survivors. The three-year probability of TRM, relapse and event-free survival (EFS) is 28{\%}, 40{\%} and 42{\%} respectively. In 20 of 27 evaluable patients, remission duration after second BMT was longer than after the first BMT. A diagnosis of AML was correlated with a better outcome. These data support the usefulness of second allograft in selected patients with AML relapsing after a first BMT.",
keywords = "Acute leukemia, Relapse, Second BMT",
author = "A. Bosi and S. Bacci and R. Miniero and F. Locatelli and D. Laszlo and G. Longo and A. Busca and {Van Lint}, {M. T.} and {Di Bartolomeo}, P. and A. Amici",
year = "1997",
language = "English",
volume = "11",
pages = "420--424",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Second allogeneic bone marrow transplantation in acute leukemia

T2 - A multicenter study from the Gruppo Italiano Trapianto Di Midolla Osseo (GITMO)

AU - Bosi, A.

AU - Bacci, S.

AU - Miniero, R.

AU - Locatelli, F.

AU - Laszlo, D.

AU - Longo, G.

AU - Busca, A.

AU - Van Lint, M. T.

AU - Di Bartolomeo, P.

AU - Amici, A.

PY - 1997

Y1 - 1997

N2 - Thirty-eight second allogeneic bone marrow transplants (BMT) for acute leukemia relapsed after first BMT were performed in 13 Italian centers between 1987 and 1994. Twenty-one patients had acute myelogenous leukemia (AML), 17 acute lymphoblastic leukemia (ALL); at second BMT 24 patients were in complete remission (CR) and 14 in relapse. The median time to relapse after first BMT was 10 months (range 1-70). Grade II or greater acute graft-versus-host disease (GVHD) after second transplant occurred in 34.2% of patients and a chronic GVHD in 31.5% of patients. Twenty-four patients died: seven from early transplant-related mortality (TRM), 13 from relapse and four from late toxicity. As of 31 July 1996, at a median follow-up of 47 months (range 22-85), there are 14 survivors. The three-year probability of TRM, relapse and event-free survival (EFS) is 28%, 40% and 42% respectively. In 20 of 27 evaluable patients, remission duration after second BMT was longer than after the first BMT. A diagnosis of AML was correlated with a better outcome. These data support the usefulness of second allograft in selected patients with AML relapsing after a first BMT.

AB - Thirty-eight second allogeneic bone marrow transplants (BMT) for acute leukemia relapsed after first BMT were performed in 13 Italian centers between 1987 and 1994. Twenty-one patients had acute myelogenous leukemia (AML), 17 acute lymphoblastic leukemia (ALL); at second BMT 24 patients were in complete remission (CR) and 14 in relapse. The median time to relapse after first BMT was 10 months (range 1-70). Grade II or greater acute graft-versus-host disease (GVHD) after second transplant occurred in 34.2% of patients and a chronic GVHD in 31.5% of patients. Twenty-four patients died: seven from early transplant-related mortality (TRM), 13 from relapse and four from late toxicity. As of 31 July 1996, at a median follow-up of 47 months (range 22-85), there are 14 survivors. The three-year probability of TRM, relapse and event-free survival (EFS) is 28%, 40% and 42% respectively. In 20 of 27 evaluable patients, remission duration after second BMT was longer than after the first BMT. A diagnosis of AML was correlated with a better outcome. These data support the usefulness of second allograft in selected patients with AML relapsing after a first BMT.

KW - Acute leukemia

KW - Relapse

KW - Second BMT

UR - http://www.scopus.com/inward/record.url?scp=16944363396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944363396&partnerID=8YFLogxK

M3 - Article

C2 - 9067583

AN - SCOPUS:16944363396

VL - 11

SP - 420

EP - 424

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -